Acquired gene mutations, such as those seen in cancer, are referred to as somatic mutations. In recent years, a variety of anticancer agents have been developed that attack specific molecules in cancer cells. These agents are called molecularly-targeted agents. When a mutation occurs in the target molecule, however, the effect of these drugs may be lost, or conversely, in some cases heightened. Since tissue removed from cancer patients includes many healthy cells, highly sensitive detection technology is required to detect these gene mutations. With our system, a crushed tissue sample is simply placed into the DNA purification cartridge. The analyzer then performs a fully automated gene mutation analysis.
||Gene mutations and anticancer agents
- BCR-ABL fusion gene and Glivec, a drug used to treat chronic myelogenous leukemia
- EGFR mutation and Iressa and Tarceva, drugs used to treat non-small cell lung cancer
- KRAS, BRAF, and PIK3CA mutations and Erbitux and Vectibix, drugs used to treat colorectal cancer
- EML4-ALK fusion gene and ALK inhibitor, a drug used to treat non-small cell lung cancer
- PIK3CA mutation and mTOR or MEK inhibitor